Semax + Selank

Semax + Selank has not been approved by the U.S. Food and Drug Administration. It can only be prescribed through licensed clinicians where state law allows. Both compounds are registered medicines in the Russian Federation, where they have seen decades of clinical use.

Yes. Selank completed Phase 3 clinical trials in Russia and is registered there as a prescription anxiolytic for generalized anxiety disorder. Semax has been used clinically in Russia for stroke recovery and cognitive impairment for decades. A 2020 study published in the European Neuropsychopharmacology examined the effects of both compounds on brain functional connectivity in 52 healthy human subjects using fMRI, finding measurable effects on circuits associated with anxiety and executive function. Most of the broader research comes from Russian clinical and preclinical literature; large-scale English-language trials remain limited.

The combination is designed to address two things that often compete: cognitive sharpness and emotional calm. Semax appears to support focus, memory, and mental energy by promoting neurotrophic activity in the brain -- essentially helping neurons communicate and adapt more effectively. Selank appears to reduce anxiety and stress reactivity through the GABA system, promoting calm without sedation. Together, they are intended for patients who need to perform at a high cognitive level while managing the stress load that often comes with it.

Based on available research, both Semax and Selank appear to be well-tolerated, with mild side effect profiles at clinical doses. Selank in particular has been specifically noted in peer-reviewed literature to lack the sedation, dependence, and withdrawal risks associated with conventional anxiolytics. As always at AIRA, use is under the supervision of a licensed physician who will evaluate your health history before prescribing.

Semax + Selank is not recommended for individuals who are pregnant or breastfeeding. It may also be unsuitable for those with certain neurological or psychiatric conditions, sensitivity to neuropeptide compounds, or those currently taking medications that affect serotonin, dopamine, or GABA pathways. Your prescribing clinician will review your full health history and current medications before recommending this protocol.

Both compounds are typically administered via subcutaneous injection. Your AIRA clinician will determine the appropriate protocol for your health goals and individual response. AIRA does not provide specific dosing guidance on this page; all protocols are determined by your prescribing physician.

Semax + Selank may complement other peptide protocols depending on your goals and current regimen. Because both compounds influence neurotransmitter systems, your clinician will carefully evaluate any overlap or interaction with existing treatments before recommending additions. This is especially important for patients currently using medications that affect mood, focus, or anxiety.